Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)

Q: What does CUSIP 004890109 represent in this 13F holders report?

CUSIP 004890109 is the security identifier for ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q1 2025?

60 institutional investors reported ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q1 2025. Use the holders table for investor-level position and value details.

CUSIP: 004890109

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 42,655,924
Total 13F shares: 22,517,048
Share change: -732,698
Total reported value: $45,710,668
Price per share: $2.03
Number of holders: 60
Value change: -$2,113,900
Number of buys: 21
Number of sells: 27

Quarterly Holders Quick Answers

What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2025
Previous quarter: Q4 2024

Recent filing periods for CUSIP 004890109:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RA CAPITAL MANAGEMENT, L.P.	13F	Company	20%	8,340,508	$50,209,858	—	31 Dec 2024	13F
PERCEPTIVE ADVISORS LLC	13F	Company	13%	5,360,858	$32,272,365	—	31 Dec 2024	13F
Kristina Masson	3/4/5	EVP - Business Operations, Director	— class O/S missing	2,819,375	$19,792,013	—	14 Aug 2024	3/4/5
Chione Ltd	3/4/5	10%+ Owner	— class O/S missing	3,848,632	$16,741,549	—	26 Jun 2023	3/4/5
Sands Capital Alternatives, LLC	13F	Company	5%	2,122,605	$12,778,082	—	31 Dec 2024	13F
CITADEL ADVISORS LLC	13F	Company	5%	2,119,646	$12,760,269	—	31 Dec 2024	13F
BlackRock, Inc.	13F	Company	2.2%	945,496	$5,691,886	—	31 Dec 2024	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	2.1%	888,130	$5,346,543	—	31 Dec 2024	13F
VANGUARD GROUP INC	13F	Company	1.6%	671,625	$4,043,182	—	31 Dec 2024	13F
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	3/4/5	10%+ Owner	— class O/S missing	888,130	$3,863,366	—	17 Nov 2022	3/4/5
MARSHALL WACE, LLP	13F	Company	1.4%	597,794	$3,598,720	—	31 Dec 2024	13F
ACORN CAPITAL ADVISORS, LLC	13F	Company	0.95%	405,237	$2,439,527	—	31 Dec 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.71%	301,389	$1,814,874	—	31 Dec 2024	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.56%	237,552	$1,430,063	—	31 Dec 2024	13F
STATE STREET CORP	13F	Company	0.55%	236,601	$1,424,338	—	31 Dec 2024	13F
NORTHERN TRUST CORP	13F	Company	0.28%	117,323	$706,284	—	31 Dec 2024	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.27%	113,840	$685,317	—	31 Dec 2024	13F
DAFNA Capital Management LLC	13F	Company	0.26%	112,414	$676,732	—	31 Dec 2024	13F
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	13F	Company	0.24%	102,784	$618,760	—	31 Dec 2024	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.17%	74,600	$449,092	—	31 Dec 2024	13F
BAKER BROS. ADVISORS LP	13F	Company	0.12%	52,885	$318,368	—	31 Dec 2024	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.12%	49,400	$297,388	—	31 Dec 2024	13F
BARCLAYS PLC	13F	Company	0.09%	38,091	$229,309	—	31 Dec 2024	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.09%	37,063	$223,119	—	31 Dec 2024	13F
MORGAN STANLEY	13F	Company	0.08%	34,731	$209,081	—	31 Dec 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.07%	31,106	$187,258	—	31 Dec 2024	13F
Bank of New York Mellon Corp	13F	Company	0.06%	27,635	$166,363	—	31 Dec 2024	13F
JPMORGAN CHASE & CO	13F	Company	0.06%	25,809	$155,370	—	31 Dec 2024	13F
Rasmus Holm-Jorgensen	3/4/5	Chief Financial Officer	— mixed-class rows	135,397 mixed-class rows	$141,397	—	01 Mar 2025	3/4/5
EXCHANGE TRADED CONCEPTS, LLC	13F	Company	0.05%	20,348	$122,495	—	31 Dec 2024	13F
RHUMBLINE ADVISERS	13F	Company	0.04%	17,755	$106,875	—	31 Dec 2024	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.04%	17,588	$105,880	—	31 Dec 2024	13F
Trexquant Investment LP	13F	Company	0.04%	16,871	$101,563	—	31 Dec 2024	13F
Pale Fire Capital SE	13F	Company	0.04%	15,235	$91,715	—	31 Dec 2024	13F
UBS Group AG	13F	Company	0.03%	14,217	$85,587	—	31 Dec 2024	13F
Nuveen Asset Management, LLC	13F	Company	0.03%	13,402	$80,680	—	31 Dec 2024	13F
Marex Group plc	13F	Company	0.03%	13,187	$79,386	—	31 Dec 2024	13F
CITIGROUP INC	13F	Company	0.03%	12,332	$74,238	—	31 Dec 2024	13F
Corton Capital Inc.	13F	Company	0.03%	12,159	$73,197	—	31 Dec 2024	13F
WEALTHEDGE INVESTMENT ADVISORS, LLC	13F	Company	0.03%	10,857	$65,359	—	31 Dec 2024	13F
AAF Wealth Management, LLC	13F	Company	0.03%	10,678	$64,282	—	31 Dec 2024	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.02%	6,933	$41,737	—	31 Dec 2024	13F
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	13F	Company	0.02%	6,775	$40,786	—	31 Dec 2024	13F
China Universal Asset Management Co., Ltd.	13F	Company	0.02%	6,602	$39,744	—	31 Dec 2024	13F
Corebridge Financial, Inc.	13F	Company	0.01%	5,873	$35,355	—	31 Dec 2024	13F
FMR LLC	13F	Company	0.01%	2,933	$17,657	—	31 Dec 2024	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.01%	2,314	$13,930	—	31 Dec 2024	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	1,941	$11,685	—	31 Dec 2024	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	1,766	$10,631	—	31 Dec 2024	13F
ROYAL BANK OF CANADA	13F	Company	0%	1,638	$10,000	—	31 Dec 2024	13F

Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q1 2025

As of 31 Mar 2025, Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by 60 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 22,517,048 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, BlackRock, Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, MARSHALL WACE, LLP, ACORN CAPITAL ADVISORS, LLC, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 61 institutional shareholders reporting positions in this security for the Q1 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 holders

Q1 2025 holders

Holder diff

Investor	Q4 2024 Shares	Q1 2025 Shares	Share Diff	Share Chg %	Q4 2024 Value $	Q1 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.